Under the cold, clinical glow of his office lights, I received the call that set the next challenge into motion—a biotech firm couldn’t get another round of funding after the FDA approval failed, buried under a mountain of debt and regulatory scrutiny. The voice on the other end was Jerri, a friendly Venture Capitalist I’d...